肺表面活性物质预防早产儿呼吸窘迫综合症的临床观察

摘要

Objective To observe the clinical effect of pulmonary surfactant in the prevention of prema-ture infants with respiratory distress syndrome. Methods 120 preterm infants were divided into two groups. All pa-tients were given conventional treatment, and the experiment group was additionally treated with Curosurf. Results The average duration of ventilation, duration of oxygen therapy and hospital stay were obviously shorter in the experi-ment group than in the control group (P<0. 01). The incidence of ventilator-associated pneumonia, pulmonary air leaks and retinopathy was significantly lower in the experiment group than in the control group (P<0. 05). The cure rate was higher and the mortality and NRDS incidence was significantly lower in the experiment group than in the con-trol group ( P<0. 01 ) . Conclusion Pulmonary surfactant has good curative effect to prevent respiratory distress syndrome in premature infants, which can quickly improve lung function and the compliance of lung in children, and reduce the incidence of complications and mortality.%目的：对肺表面活性物质固尔苏应用于早产儿呼吸窘迫综合症的早期预防效果进行观察及分析。方法选取早产儿病例120例，根据患儿家长意愿分组为固尔苏组62例和对照组58例。在常规进行心电监测、入恒温箱、抗感染等治疗基础上，对照组不应用固尔苏，固尔苏组给予固尔苏用药治疗。结果固尔苏组患儿的平均通气时间、氧疗时间和住院时间明显短于对照组( P<0．01)；固尔苏组患儿呼吸机相关性肺炎、肺气漏和视网膜病变发病率明显低于对照组(P<0．05)；固尔苏组患儿治愈率明显高于对照组，致死率和NRDS发生率明显低于对照组(P<0．01)。结论肺表面活性物质预防早产儿呼吸窘迫综合症具有较好的疗效，可快速改善患儿肺功能、提高肺顺应性，并且降低并发症的发生以及致死率。